1. Home
  2. IFRX vs BRLS Comparison

IFRX vs BRLS Comparison

Compare IFRX & BRLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • BRLS
  • Stock Information
  • Founded
  • IFRX 2007
  • BRLS 2019
  • Country
  • IFRX Germany
  • BRLS Canada
  • Employees
  • IFRX N/A
  • BRLS N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • BRLS
  • Sector
  • IFRX Health Care
  • BRLS
  • Exchange
  • IFRX Nasdaq
  • BRLS NYSE
  • Market Cap
  • IFRX 117.8M
  • BRLS 117.8M
  • IPO Year
  • IFRX 2017
  • BRLS N/A
  • Fundamental
  • Price
  • IFRX $1.83
  • BRLS $6.26
  • Analyst Decision
  • IFRX Strong Buy
  • BRLS
  • Analyst Count
  • IFRX 1
  • BRLS 0
  • Target Price
  • IFRX $8.00
  • BRLS N/A
  • AVG Volume (30 Days)
  • IFRX 498.3K
  • BRLS 5.2K
  • Earning Date
  • IFRX 03-20-2025
  • BRLS 03-07-2025
  • Dividend Yield
  • IFRX N/A
  • BRLS N/A
  • EPS Growth
  • IFRX N/A
  • BRLS N/A
  • EPS
  • IFRX N/A
  • BRLS N/A
  • Revenue
  • IFRX $187,930.00
  • BRLS $28,366,370.00
  • Revenue This Year
  • IFRX $396.02
  • BRLS N/A
  • Revenue Next Year
  • IFRX $155.22
  • BRLS N/A
  • P/E Ratio
  • IFRX N/A
  • BRLS N/A
  • Revenue Growth
  • IFRX 177.12
  • BRLS N/A
  • 52 Week Low
  • IFRX $1.17
  • BRLS $3.71
  • 52 Week High
  • IFRX $2.82
  • BRLS $11.60
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 32.97
  • BRLS 52.82
  • Support Level
  • IFRX $1.76
  • BRLS $6.00
  • Resistance Level
  • IFRX $1.98
  • BRLS $6.67
  • Average True Range (ATR)
  • IFRX 0.19
  • BRLS 0.12
  • MACD
  • IFRX -0.08
  • BRLS 0.02
  • Stochastic Oscillator
  • IFRX 6.65
  • BRLS 52.09

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About BRLS BOREALIS FOODS INC

Borealis Foods Inc is a food technology company that has developed high-quality, affordable, sustainable, and nutritious ready-to-eat meals. It is a mission-driven company committed to utilizing its products to help solve national and global food security and nutrition challenges. Its commitment to nutrition, affordability, and sustainability reflects its goal of positively impacting both human life and the planet. Through the development and launch of its ready-made ramen, featuring 20 grams of complete plant-based protein per serving, Borealis is developing advanced solutions to address global food challenges.

Share on Social Networks: